Oncorus Inc. in brief
Oncorus Inc. is an unlisted company in the Biotechnology industry, based in Massachusetts, USA. In the year to Dec 2020 it had sales of $0 M and a net loss of $57 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Oncorus Inc.
Oncorus is a Biopharmaceutical company focused on developing next generation, systemically active viral immunotherapies to transform outcomes for cancer patients. It is having 51 employees as on 2020. The headquarters is in USA.
Oncorus Inc. timeline
- 2020
- 🔔· approximateInitial public offering on Nasdaq
Events of Oncorus Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Oncorus Inc.
- Acquisitions and changes
- No longer listed: ticker ONCR is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #2,448 (Jan 2021) · #4,280 (Jan 2022) · #5,674 (Dec 2022)
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-57 M
Dec-2020 ending year
H-1B hiring at Oncorus Inc.#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $109 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| SCIENTISTBiological Scientists, All Other | 1 | $109 K |
Where: Cambridge, MA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ONCORUS, INC.
How Oncorus Inc. compares in Biotechnology
- Revenue$0 M · higher than 0% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Oncorus Inc.🇺🇸 | $7 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Dec 25, 2022 (last known)
- Annual results:
- Dec-2020 ending year
- Balance sheet:
- Dec-2020 ending year
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Oncorus Inc.? Verify and update this profile — free
Show Oncorus Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.